⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586527 | 0.88 | RIPK1 (0.31) | — | |
| SCHEMBL619575 | 0.86 | TYMP (0.33) | — | |
| SCHEMBL3504553 | 0.85 | — | — | |
| SCHEMBL5345793 | 0.85 | SMYD3 (0.38) | — | |
| SCHEMBL23649353 | 0.84 | AKR1C3 (0.34) | — | |
| SCHEMBL1810381 | 0.83 | NR1H2 (0.33) | — | |
| SCHEMBL18322450 | 0.83 | RIPK1 (0.34) | — | |
| SCHEMBL3503869 | 0.82 | ALDH1A1 (0.31) | — | |
| SCHEMBL23649341 | 0.82 | — | — | |
| SCHEMBL482006 | 0.81 | NCF1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230151005-A1 | HETERO-TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-18 | — | — | US | disclosed |
| WO-2023049697-A1 | HETERO-TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20110251172-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. | 2011-10-13 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| EP-1912989-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |